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Chronic kidney diseaseAbstract Objectives: This study sought to examine the immediate and short term outcome
(6 months) of percutaneous coronary interventions (PCIs) in patients with advanced chronic kidney
disease (CKD).
Background: PCI is established as a safe and effective option to treat patients with coronary
artery disease. Difficulties and complications are known to be higher during PCI in patients with
chronic kidney disease (CKD). Few data exist on the immediate and short term outcome of PCI
in patients with advanced chronic kidney disease (creatinine clearance (Cr Cl) <30 ml/min).
Methods: 642 consecutive patients underwent PCIs. Patients were classified according to crea-
tinine clearance into 3 groups. Group 1, Cr Cl >70, Group 2, Cr Cl <70 and >30, Group 3,
Cr Cl <30. Group 1 included 332 (51.7%), group 2 included 292 patients (45.5%) and group 3
included 18 patients (2.8%). Immediate and short term follow-up (6 months) was done for death,
myocardial infarction, bleeding, TIA or cerebro-vascular stroke, contrast induced nephropathy
(CIN) and repeated revascularization.
Results: Although immediate angiographic and procedural success was high (>93%) in all
groups, as compared to patients in group 1 and 2, patients in group 3 had higher in-hospital mor-
bidity (61% vs 0.9% and 8% for groups 3, 1 and 2 respectively P< 0.0001, and mortality (5.6% vs
0.6% and 0.6% for groups 3, 1 and 2 respectively P< 0.001) and short term, mortality was 28% vs
1.8% and 5.8% for in groups 3, 1 and 2 respectively, p< 0.00002.
Conclusion: PCI for patient with advanced CKD carries a very high risk. It should be done on
individual basis. Outcome is expected to be poor and short term benefit is expected to be limited.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Chronic renal failure is associated with a high cardiovascular
mortality. The mortality rate in the first year after initiationc kidney
Figure 2 Follow up data.
Table 1 Comparison between the three groups by creatinine
clearance.
Cr Cl
N %
>70. 332 51.71
69–30. 292 45.48
<30. 18 2.80
Total 642 100.00
2 H. Kandil et al.of dialysis is 24%, over half of these deaths are attributable to
cardiovascular diseases [1]. The association between renal fail-
ure and CAD is well established, but the precise mechanisms of
this interaction are not clearly understood. Explanations of
this interaction include the greater frequency of risk factors,
such as diabetes mellitus and hypertension, in patients with
renal insufficiency, as well as the effects of renal failure on
lipids, oxidative stress, homocysteine and fibrinogen [2].
Nearly 11 million Americans have mild renal insufficiency,
over 30 times the number of people in the dialysis population,
and this number continues to grow.
Patients and methods
All patients underwent PCI at Kobry El-Kobba Military
Hospital in the period of one year with follow up, up to six
months. This registry included baseline demographic, clinical
and angiographic data. Follow-up data were collected using
a standardized questionnaire, at six months after the proce-
dure. All adverse events were confirmed by reviewing the
records of the patients followed at our institution and by con-
tacting the patients at the outpatient clinic.
Inclusion criteria
All patients who underwent PCI in the period of one year were
eligible for inclusion. For patients who underwent more than
one revascularization procedure during the study period, only
the first intervention will be included for analysis.
Exclusion criteria
1- Patients with past history of renal transplantation.
2- Patients who had acute renal failure before the PCI pro-
cedure (as defined by a rise in serum creatinine of 1 mg/
dl above the baseline value).
3- Patients who did not have their creatinine level mea-
sured 24–48 h before the procedure.
4- Patients who will undergo PCI within 24 h after myocar-
dial infarction.
5- Patients who had pre-procedural shock.
6- All patients who denied research authorization will be
also excluded.Figure 1 In hospital events.
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All patients were investigated by:
1. History taking & clinical examination fulfilling the fol-
lowing data:Age, Sex, Hypertension, Diabetes Mellitus,
Dyslipidemia, Smoking, Past history of IHD, Past his-
tory of renal disease, Past history of TIA or cerebro-
vascular stroke, Indications of PCI (STEMI, NSTEMI,
UA, CSA, positive functional test for ischemia),Cardiac
examination to exclude signs of decompensation.
2. 12 Lead ECG with special concern for the Ischemic
manifestations in the form of Q, ST, T changes.
3. Cardiac enzymes were done before & 24 h after the
procedure.
4. Routine laboratory investigations with special concern
to Serum creatinine.
5. All patients underwent percutaneous coronary interven-
tion (PCI) with documentation of the following data:
Number of diseased vessel, Coronary vessel treated,
Device used (balloon, stent, Rotablator), Angiographic
success, Procedural success, Complete revascularization.
6. Follow up after six months included Death, STEMI,
NSTEMI,TIA or cerebro-vascular stroke, Contrast
induced nephropathy (CIN), Repeated
revascularization.
7. Assessment of renal function. Using the creatinine level
obtained 24–48 h before the angiogram, renal function
was assessed by the estimated creatinine clearance, usingf percutaneous coronary interventions in patients with advanced chronic kidney
08.009
Table 2 Effect of diabetes mellitus on creatinine clearance.
Diabetes mellitus Cr Cl
>70 69–30 <30 Total
Positive N 68 64 6 138
% 20.48 21.92 33.33 21.50
Negative N 264 228 12 504
% 79.52 78.08 66.67 78.50
Total N 332 292 18 642
% 100.00 100.00 100.00 100.00
Chi-square X2 1.728
P-value 0.421
Table 3 Effect of hypertension on creatinine clearance.
Hypertension Cr Cl
>70 69–30 <30 Total
Positive N 182 189 14 385
% 54.82 64.73 77.78 59.97
Negative N 150 103 4 257
% 45.18 35.27 22.22 40.03
Total N 332 292 18 642
% 100.00 100.00 100.00 100.00
Chi-square X2 8.798
P-value 0.012
Table 4 Angiographic success.
Angiographic success Cr Cl
>70 69–30 <30 Total
Yes N 318 276 17 611
% 95.78 94.52 94.44 95.17
No N 14 16 1 31
% 4.22 5.48 5.56 4.83
Total N 332 292 18 642
% 100.00 100.00 100.00 100.00
Chi-square X2 0.560
P-value 0.755
Limited value and prohibitive risk of percutaneous coronary interventions in patients with advanced chronic kidney disease 3the Cockroft–Gault formula:Creatinine clearance (ml/
min) = [([140  age]  weight [kg])/72  serum crea-
tinine (mg/dl)] ( 0.85 for women) [3].
8. Patients were categorized by level of creatinine clearance
(>70, 50 to 69, 30 to 49 and <30 ml/min).
9. Angiographic success was defined as achievement of
TIMI III flow with residual stenosis <20% [2].
10. Procedural success was defined as angiographic success
without death, Q-wave MI or coronary artery bypass
graft surgery (CABG) during the initial hospitalization
[2].
11. Contrast Induced Nephropathy (CIN) was defined as
increase in serum creatinine levels that begins at
48–72 h, peak at 3–5 days, and returns to baseline within
another 3–5 days [4].Please cite this article in press as: H. Kandil et al., Limited value and prohibitive risk o
disease, Egypt. J. Chest Dis. Tuberc. (2016), http://dx.doi.org/10.1016/j.ejcdt.2016.012. Chronic kidney disease was defined as: evidence of struc-
tural or functional kidney abnormalities (abnormal uri-
nalysis, imaging studies, or histology) that persist for at
least three months, with or without a decreased GFR (as
defined by a GFR of less than 60 mL/min per 1.73 m2).
The most common manifestation of kidney damage is
persistent albuminuria, including microalbuminuria [5].
13. Based upon this definitions, the following was the rec-
ommended classification of chronic kidney disease:f percu
8.009 Stage 1 disease is definedbyanormalGFR(greater than
90 mL/min per 1.73 m2) and persistent albuminuria.
 Stage 2 disease is a GFR between 60 and 89 mL/min
per 1.73 m2 and persistent albuminuria.
 Stage 3 disease is a GFR between 30 and 59 mL/min
per 1.73 m2.taneous coronary interventions in patients with advanced chronic kidney
Table 5 Procedural success.
Procedural success Cr Cl
>70 69–30 <30 Total
Yes N 315 272 16 603
% 94.88 93.15 88.89 93.93
No N 17 20 2 39
% 5.12 6.85 11.11 6.07
Total N 332 292 18 642
% 100.00 100.00 100.00 100.00
Chi-square X2 1.637
P-value 0.441
Table 6 In hospital events.
In Hospital events Cr Cl Chi-square
>70 69–30 <30 Total X2 P-value
Death N 2 2 1 5 5.482 0.064
% 0.60 0.68 5.56 0.78
MI N 1 2 0 3 0.579 0.748
% 0.30 0.68 0.00 0.47
CABG N 0 0 0 0 – –
% 0.00 0.00 0.00 0.00
CVS or TIA N 3 3 1 7 3.446 0.178
% 0.90 1.03 5.56 1.09
CIN N 3 25 10 38 98.298 <0.001
% 0.90 8.56 55.56 5.92
4 H. Kandil et al.
Please
disease Stage 4 disease is a GFR between 15 and 29 mL/min
per 1.73 m2.
 Stage 5 disease is a GFR of less than 15 mL/min per
1.73 m2 or end-stage renal disease [5].Results
Demographic data
Our study included 642 patients, 589 males and 53 females col-
lected from Kobry El Kobba Military Hospital in the period
from January 2013 to December 2013.The age of our study
population ranged from 41 to 74 years. Patients were classified
according to creatinine clearance into 3 groups. Group 1, Cr
Cl >70, Group 2, Cr Cl <70 and >30, Group 3, Cr Cl
<30. Group 1 included 332 (51.7%), group 2 included 292
patients (45.5%) and group 3 included 18 patients (2.8%).
Immediate and short term follow-up (6 months) was done
for death, myocardial infarction, bleeding, TIA or cerebro-
vascular stroke, contrast induced nephropathy (CIN) and
repeated revascularization.
Table 1 shows that patients in group 1 have more creatinine
clearance than patients in group 2 and group 3.cite this article in press as: H. Kandil et al., Limited value and prohibitive risk o
, Egypt. J. Chest Dis. Tuberc. (2016), http://dx.doi.org/10.1016/j.ejcdt.2016.Table 2 shows that patients in group 3 have more
prevalence of diabetes mellitus than in patients in group 1
and group 2.
Table 3 shows that patients in group 3 have more preva-
lence of hypertension than in patients in group 1 and group 2.
Table 4 shows that all groups have high percentage of
angiographic success regardless the level of creatinine
clearance.
Table 5 shows that all groups have high percentage of pro-
cedural success but it was relatively low in group 3.
Table 6 shows that in hospital events was relatively high in
group 3 compared to group 1 and group 2 but without statis-
tical significance except for the development of CIN which was
significantly higher in group 3.
Fig. 1 shows that in hospital events was relatively high in
group 3 compared to group 1 and group 2 but without statis-
tical significance except for the development of CIN which was
significantly higher in group 3.
Table 7 shows that after six months of follow up, all com-
plications were higher in group 3 compared to group 1 and
group 2 with significant higher rate of death and progressive
kidney disease in comparison to non significant higher rate
of MI, Cerebrovascular events and need for repeated
revascularization.f percutaneous coronary interventions in patients with advanced chronic kidney
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Table 7 Follow up data.
Follow up Cr Cl Chi-square
>70 69–30 <30 Total X2 P-value
Death N 6 17 5 28 30.348 <0.001
% 1.81 5.82 27.78 4.36
MI N 26 32 3 61 2.873 0.237
% 7.83 10.96 16.67 9.50
CVS or TIA N 3 7 1 11 3.682 0.158
% 0.90 2.40 5.56 1.71
Progressive KD N 3 25 11 39 114.281 <0.001
% 0.90 8.56 61.11 6.07
Repeated revascularization N 29 38 4 71 5.238 0.072
% 8.73 13.01 22.22 11.06
Limited value and prohibitive risk of percutaneous coronary interventions in patients with advanced chronic kidney disease 5Fig. 2 shows that in hospital events was relatively high in
group 3 compared to group 1 and group 2 but without statis-
tical significance except for the development of CIN which was
significantly higher in group 3.
Discussion
Our results showed that diabetes mellitus has strong effect on
reduction of creatinine clearance but is not statistically signif-
icant. That was consistent with the study done by Odutola TA,
who studied creatinine clearance in 46 male and 38 female
patients with diabetes mellitus (DM) and proved that the pres-
ence of diabetic complications and the mode of therapy of the
diabetic state did not significantly affect the glomerular filtra-
tion rate [13]. Our study proved that that hypertension has
strong effect on reduction of creatinine clearance with statisti-
cally significant relation between hypertension and reduction
of creatinine clearance. These results was consistent with the
study done by Matti Manttari who studied the effect of hyper-
tension on 2702 middle-aged men without renal disease, and
proved that Renal function deteriorated 3% on average during
the 5-year study, and hypertension accelerated this change
(Ma¨ntta¨ri et al., 1995). Regarding the follow up of patients
with lower creatinine clearance who underwent PCI, The
results of our study showed that death and myocardial infarc-
tion was more frequent in patients with lower creatinine clear-
ance with statistically significant relationship between death
and low creatinine clearance. That was consistent with the
results of the study done by Faisal et al. who studied in-
Hospital and 1-Year Outcomes Among Percutaneous Coron-
ary Intervention Patients With Chronic Kidney Disease and
evaluated the influence of CKD on major cardiovascular
events and bleeding complications in 4791 unselected ‘‘real-
world” patients undergoing PCI and revealed that lower CrCl
was associated with more frequent death or myocardial infarc-
tion (MI) during the initial hospital stay and at 1 year. So, he
proved that renal function is an independent and powerful pre-
dictor of bleeding and ischemic complications in the era of
DES and contemporary antithrombotic therapy in patients
undergoing PCI [6]. In another study to show the impact of
renal insufficiency on a total of 1382 patients who underwent
PCI, mortality rates were significantly higher for patients withPlease cite this article in press as: H. Kandil et al., Limited value and prohibitive risk o
disease, Egypt. J. Chest Dis. Tuberc. (2016), http://dx.doi.org/10.1016/j.ejcdt.2016.0moderate RI compared to mild RI and normal kidney function
at 6 years follow up [7]. Our results showed that during follow
up of patients with lower creatinine clearance, they had signif-
icant rate of mortality in comparison to patients normal kid-
ney function or patients with mild renal impairment. That
was consistent with another study done by Zhang RY, who
studied long term clinical outcomes in patients with moderate
renal insufficiency undergoing percutaneous coronary inter-
vention and he studied major adverse cardiac events and
causes of mortality for 1012 patients undergoing percutaneous
intervention, and he proved that during follow-up (average
17 months) after successful PCI, all causes of death and car-
diac death were significantly higher in renal insufficiency group
than in control group, and for patients with moderate renal
insufficiency, drug-eluting stent implantation reduced signifi-
cantly all causes of death and occurrence of major cardiac
adverse events compared with bare metal stents, so he stated
that moderate renal insufficiency is an important clinical factor
influencing the mortality after PCI in patients with coronary
artery disease and the use of drug-eluting stents should be
the preferred therapy for the improvement of long-term out-
comes in such patients [8]. Our results showed that mortality
was significantly higher among patients with the lowest crea-
tinine clearance and also cerebrovascular accidents were more
frequent in patients with lower creatinine clearance but yet is
not statistically significant. That was partially consistent with
the results of the study done by Patrik et al. who performed
retrospective evaluation of 1567 patients with symptomatic
coronary artery disease undergoing PCI, 648 of whom had
stage 3–5 CKD and he found that in a multivariate survival
analysis that included 1335 (85%) of the cohort, stage 3–5
CKD and low response to clopidogrel were independent pre-
dictors of the primary end point (composite of myocardial
infarction, ischemic stroke, and death within 1 year) [9]. Our
results showed that during hospital stay mortality rate was
high in patients with lower creatinine clearance but with no
statistically significant relationship, but that was not consistent
with the results published by Clare et al., who studied 11 953
patients who were stratified to those with or without at least
moderate CKD and he showed that In-hospital mortality
and MACE were significantly increased in CKD. On the other
hand our results was matching with his results regarding longf percutaneous coronary interventions in patients with advanced chronic kidney
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6 H. Kandil et al.term follow up which revealed that CKD was an independent
predictor of late mortality and MACE and also DES use was
associated with a significant reduction in both [11].
Conclusion
Although immediate angiographic and procedural success was
high (>93%) in all groups, as compared to patients in group 1
and 2, patients in group 3 had higher in-hospital morbidity
(61% vs 0.9% and 8% for groups 3, 1 and 2 respectively,
and mortality (5.6% vs 0.6% and 0.6% for groups 3, 1 and
2 respectively) and short term, mortality was 28% vs 1.8%
and 5.8% for in groups 3, 1 and 2 respectively. PCI for patient
with advanced CKD carries a very high risk. It should be done
on individual basis. Outcome is expected to be poor and short
term benefit is expected to be limited.
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